Determination of the Cancer Genome Atlas (TCGA) Endometrial Cancer Molecular Subtypes Using the Variant Interpretation and Clinical Decision Support Software MH Guide.

TCGA endometrial cancer exome sequencing molecular subtypes

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
30 Mar 2023
Historique:
received: 19 12 2022
revised: 09 03 2023
accepted: 14 03 2023
medline: 14 4 2023
entrez: 13 4 2023
pubmed: 14 4 2023
Statut: epublish

Résumé

The Cancer Genome Atlas (TCGA) network (United States National Cancer Institute) identified four molecular endometrial cancer (EC) subtypes using an extensive multi-method approach. The aim of this study was to determine the four TCGA EC molecular subtypes using a single-method whole-exome sequencing (WES)-based approach provided by MH Guide (Molecular Health, Heidelberg, Germany). WES and clinical data of n = 232 EC patients were obtained from TCGA. The four TCGA EC molecular subtypes designated as (i) Mutated Polymerase ε (POLE), (ii) Microsatellite Instability (MSI), (iii) Copy Number (CN) low and, (iv) CN-high were determined using the MH Guide software. The prognostic value of the subtypes determined by MH Guide were compared with the TCGA classification. Analysis of WES data using the MH Guide software led to the precise identification of the four EC molecular subtypes analogous to the TCGA classification. Both approaches displayed high concordance in terms of prognostic significance. The multi-method-based TCGA EC molecular subtypes can reliably be reproduced by the single-method-based MH Guide approach. The easy-to-implement single-method MH Guide approach represents a promising diagnostic tool.

Sections du résumé

BACKGROUND BACKGROUND
The Cancer Genome Atlas (TCGA) network (United States National Cancer Institute) identified four molecular endometrial cancer (EC) subtypes using an extensive multi-method approach. The aim of this study was to determine the four TCGA EC molecular subtypes using a single-method whole-exome sequencing (WES)-based approach provided by MH Guide (Molecular Health, Heidelberg, Germany).
METHODS METHODS
WES and clinical data of n = 232 EC patients were obtained from TCGA. The four TCGA EC molecular subtypes designated as (i) Mutated Polymerase ε (POLE), (ii) Microsatellite Instability (MSI), (iii) Copy Number (CN) low and, (iv) CN-high were determined using the MH Guide software. The prognostic value of the subtypes determined by MH Guide were compared with the TCGA classification.
RESULTS RESULTS
Analysis of WES data using the MH Guide software led to the precise identification of the four EC molecular subtypes analogous to the TCGA classification. Both approaches displayed high concordance in terms of prognostic significance.
CONCLUSIONS CONCLUSIONS
The multi-method-based TCGA EC molecular subtypes can reliably be reproduced by the single-method-based MH Guide approach. The easy-to-implement single-method MH Guide approach represents a promising diagnostic tool.

Identifiants

pubmed: 37046713
pii: cancers15072053
doi: 10.3390/cancers15072053
pmc: PMC10093381
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Arch Pathol Lab Med. 2016 Aug;140(8):836-43
pubmed: 27139150
Front Oncol. 2021 Jun 03;11:668151
pubmed: 34150634
Semin Diagn Pathol. 2022 Jan;39(1):58-77
pubmed: 34750021
Arch Gynecol Obstet. 2016 Nov;294(5):889-895
pubmed: 27637583
J Clin Oncol. 2019 Feb 1;37(4):286-295
pubmed: 30376427
Clin Cancer Res. 2016 Aug 15;22(16):4215-24
pubmed: 27006490
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Gynecol Oncol. 2018 Sep;150(3):569-580
pubmed: 29843906
J Clin Oncol. 2020 Oct 10;38(29):3388-3397
pubmed: 32749941
Radiother Oncol. 2021 Feb;155:160-166
pubmed: 33159971
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Gynecol Oncol. 2018 Oct;151(1):69-75
pubmed: 30078506
Gynecol Oncol. 1983 Feb;15(1):10-7
pubmed: 6822361
J Clin Oncol. 2006 Oct 10;24(29):4783-91
pubmed: 17028294
Mod Pathol. 2000 Mar;13(3):295-308
pubmed: 10757340
Endocr Relat Cancer. 2000 Dec;7(4):227-42
pubmed: 11174845
Lancet Oncol. 2018 Mar;19(3):295-309
pubmed: 29449189
Hum Pathol. 2021 May;111:98-109
pubmed: 33662372
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Chemother Pharmacol. 2013 Nov;72(5):975-83
pubmed: 23995698
BMC Cancer. 2012 Mar 30;12:128
pubmed: 22459016
Clin Obstet Gynecol. 2011 Jun;54(2):278-91
pubmed: 21508697

Auteurs

Alexander Mustea (A)

Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.

Damian J Ralser (DJ)

Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.

Eva Egger (E)

Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.

Ulrike Ziehm (U)

Molecular Health, Kurfuersten-Anlage 21, 69115 Heidelberg, Germany.

Sonia Vivas (S)

Molecular Health, Kurfuersten-Anlage 21, 69115 Heidelberg, Germany.

Stephan Brock (S)

Molecular Health, Kurfuersten-Anlage 21, 69115 Heidelberg, Germany.

David Jackson (D)

Molecular Health, Kurfuersten-Anlage 21, 69115 Heidelberg, Germany.

Mateja Condic (M)

Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.

Christian Meisel (C)

Molecular Health, Kurfuersten-Anlage 21, 69115 Heidelberg, Germany.

Lucia Otten (L)

Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.

Anna Laib (A)

Molecular Health, Kurfuersten-Anlage 21, 69115 Heidelberg, Germany.

Miguel Cubas Cordova (MC)

Molecular Health, Kurfuersten-Anlage 21, 69115 Heidelberg, Germany.

Rahel Hartmann (R)

Molecular Health, Kurfuersten-Anlage 21, 69115 Heidelberg, Germany.

Martin A Stein (MA)

Molecular Health, Kurfuersten-Anlage 21, 69115 Heidelberg, Germany.

Dominique Koensgen (D)

Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.

Matthias B Stope (MB)

Department of Gynecology and Gynecological Oncology, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.

Classifications MeSH